Extranodal MALT Lymphoma in the Oral Cavity: A Series of Three Cases with Review of Literature

Kaur, Ramandeep; Shetty, Dhanlaxmi; Bagal, Bhausaheb; Gujral, Sumeet; Sengar, Manju; Laskar, Siddhartha; Nayak, Lingaraj; Shet, Tanuja

doi:10.1007/s12105-022-01461-6

Cited by 2 publications

(4 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The two most common histological subtypes of NHL are a clinically aggressive diffuse large B-cell lymphoma and MALT lymphoma. Mucosa-associated lymphoid tissue lymphoma is an indolent B-cell neoplasm virtually always presenting in extra-nodal sites [ 3 , 7 ]. MALT lymphomas have unique clinical features and histological morphology forming lymphoepithelial lesions [ 9 ].…”

Section: Discussionmentioning

confidence: 99%

“…NHLs are a part of a heterogeneous group of malignant lymphocytic neoplasms whose prevalence has recently been increasing [ 2 ]. Primary oral cavity non-Hodgkin lymphoma is very rare and manifests in approximately 3%-5% of all NHLs [ 3 , 4 ]. Oral mucosa-associated lymphoid tissue (MALT) lymphoma is frequent in males, with the age ranging from 3 to 96 years [ 1 ].…”

Section: Introductionmentioning

confidence: 99%

“…MALT lymphoma is a non-Hodgkin lymphoma subtype and is an indolent B-cell neoplasm virtually always presenting in extra-nodal sites [ 2 , 3 , 7 ]. Risk factors for the MALT lymphomas are periodic swellings of the parotid gland, increased mononuclear cell infiltrates in the lower lip biopsy, and positive rheumatoid factors [ 8 ].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Mucosa-Associated Lymphoid Tissue Lymphoma of the Sublingual Salivary Gland: A Case Report

Aleksiejūnaitė¹,

Talijūnas²,

Zaleckas³

et al. 2023

Cureus

View full text Add to dashboard Cite

Mucosa-associated lymphoid tissue (MALT) lymphoma is a type of B-cell lineage lymphoma that can affect the head and neck region. This report presents a rare case of an extra-nodal marginal zone B-cell MALT lymphoma of a sublingual gland, diagnosed in an 18-year-old male patient. The patient had a history of ranula surgical removal on the right side of the mouth. One year after surgery, the patient presented with complaints of swelling of the left parotid gland, with no significant changes found during the examination and a self-resolving outcome. Subsequently, two years later, the patient began to complain of a fast-growing cyst under the tongue. A surgical excision of the left sublingual gland and the ranula was performed, and a final diagnosis of MALT lymphoma was rendered. The patient was referred to the department of hematology for further treatment planning and follow-up.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Mucosa-Associated Lymphoid Tissue Lymphoma of the Sublingual Salivary Gland: A Case Report

Aleksiejūnaitė¹,

Talijūnas²,

Zaleckas³

et al. 2023

Cureus

View full text Add to dashboard Cite

show abstract

“…Binding between the Fc segment of the antibody and the Fc receptor on the surface of neutrophils induces the release of a cytotoxic medium that kills tumor cells. [46,47] DCs, as the most powerful professional APCs in vivo, have a strong ability to process antigen materials and present them to T cells in the LNs to activate antitumor immunity. [48,49] The enhanced infiltration of DCs in tumors may result from the improved immunogenicity caused by Fe 3 O 4 @IR820@CpG and allow for efficient antigen capture and presentation, as evidenced by the high infiltration of DCs into the primary and distant LNs (Figure 5M,N).…”

Section: Fe 3 O 4 @Ir820@cpg Activates Anti-tumor Immune Systemsmentioning

confidence: 99%

Laser‐Activatable In Situ Vaccine Enhances Cancer‐Immunity Cycle

Wang,

You,

et al. 2023

Advanced Materials

View full text Add to dashboard Cite

The immune response in cancer reflects a series of carefully regulated events; however, current tumor immunotherapies typically address a single key aspect to enhance anti‐tumor immunity. In the present study, we developed a nanoplatform (Fe3O4@IR820@CpG)‐based immunotherapy strategy that targets the multiple key steps in cancer‐immunity cycle: 1) promotes the release of tumor‐derived proteins (TDPs), including tumor‐associated antigens and pro‐immunostimulatory factors), in addition to the direct killing effect, by photothermal (PTT) and photodynamic therapy (PDT); 2) captures the released TDPs and delivers them, together with CpG (a Toll‐like receptor 9 [TLR‐9] agonist) to antigen presenting cells (APCs) to promote antigen presentation and T cell activation; 3) enhances the tumor‐killing ability of T cells by combining with anti‐programmed death ligand 1 antibody (α‐PD‐L1), which collectively advances our outstanding of the anti‐tumor effects on colorectal, liver and breast cancers. The broad‐spectrum anti‐tumor activity of Fe3O4@IR820@CpG with α‐PD‐L1 demonstrated that optimally manipulating anti‐cancer immunity not singly but as a group provides promising clinical strategies.This article is protected by copyright. All rights reserved

show abstract

Extranodal MALT Lymphoma in the Oral Cavity: A Series of Three Cases with Review of Literature

Cited by 2 publications

References 34 publications

Mucosa-Associated Lymphoid Tissue Lymphoma of the Sublingual Salivary Gland: A Case Report

Mucosa-Associated Lymphoid Tissue Lymphoma of the Sublingual Salivary Gland: A Case Report

Laser‐Activatable In Situ Vaccine Enhances Cancer‐Immunity Cycle

Contact Info

Product

Resources

About